

Rigas G Kalaitzidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6115512/publications.pdf>

Version: 2024-02-01

39
papers

800
citations

516215

16
h-index

500791

28
g-index

39
all docs

39
docs citations

39
times ranked

1203
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade. American Journal of Nephrology, 2009, 30, 418-424.	1.4	146
2	Disturbances of Phosphate Metabolism: Another Feature of Metabolic Syndrome. American Journal of Kidney Diseases, 2005, 45, 851-858.	2.1	61
3	The role of obesity in kidney disease: recent findings and potential mechanisms. International Urology and Nephrology, 2011, 43, 771-784.	0.6	55
4	Salt sensitivity and hypertension. Journal of Human Hypertension, 2021, 35, 184-192.	1.0	51
5	Prehypertension: is it relevant for nephrologists?. Kidney International, 2010, 77, 194-200.	2.6	40
6	The Role of Statins in Chronic Kidney Disease. American Journal of Nephrology, 2011, 34, 195-202.	1.4	37
7	Treatment of Hypertension in Chronic Kidney Disease. Current Hypertension Reports, 2018, 20, 64.	1.5	34
8	Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. Journal of Clinical Hypertension, 2009, 11, 636-643.	1.0	30
9	Hypertension in Early-Stage Kidney Disease: An Update From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2009, 53, S22-S31.	2.1	30
10	Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity. International Urology and Nephrology, 2017, 49, 1401-1407.	0.6	28
11	Effects of angiotensin II receptor blockers on diabetic nephropathy. Journal of Hypertension, 2009, 27, S15-S21.	0.3	25
12	Uric acid and incident chronic kidney disease in dyslipidemic individuals. Current Medical Research and Opinion, 2018, 34, 1193-1199.	0.9	25
13	Hypomagnesemia in Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 1998, 22, 134-134.	1.4	22
14	Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. Current Opinion in Nephrology and Hypertension, 2009, 18, 386-391.	1.0	22
15	Management of hypertension in patients with diabetes: the place of angiotensinâ€”receptor blockers. Diabetes, Obesity and Metabolism, 2009, 11, 757-769.	2.2	19
16	Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. American Journal of Nephrology, 2021, 52, 693-701.	1.4	18
17	Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes. Current Vascular Pharmacology, 2012, 10, 156-161.	0.8	16
18	Should nephrologists use beta-blockers? A perspective. Nephrology Dialysis Transplantation, 2008, 24, 701-702.	0.4	15

#	ARTICLE	IF	CITATIONS
19	Effects of Nebivolol on Aortic Compliance in Patients With Diabetes and Maximal Renin Angiotensin System Blockade: The <scp>EFFORT</scp> Study. <i>Journal of Clinical Hypertension</i> , 2013, 15, 473-479.	1.0	15
20	Klotho, the Holy Grail of the kidney: from salt sensitivity to chronic kidney disease. <i>International Urology and Nephrology</i> , 2016, 48, 1657-1666.	0.6	15
21	Arterial damage and cognitive decline in chronic kidney disease patients. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1276-1284.	1.0	15
22	The current state of RAAS blockade in the treatment of hypertension and proteinuria. <i>Current Cardiology Reports</i> , 2009, 11, 436-442.	1.3	14
23	Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2010, 8, 604-611.	0.8	14
24	Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Life</i> , 2022, 12, 718.	1.1	10
25	Hyperphosphatemia and phosphate binders: effectiveness and safety. <i>Current Medical Research and Opinion</i> , 2014, 30, 109-112.	0.9	9
26	Overview of infections as an etiologic factor and complication in patients with vasculitides. <i>Rheumatology International</i> , 2022, 42, 759-770.	1.5	9
27	Are Renin-Angiotensin-Aldosterone System Blockers Distinguishable Based on Cardiovascular and Renal Outcomes in Nephropathy?. <i>Postgraduate Medicine</i> , 2009, 121, 77-88.	0.9	6
28	Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19. <i>Frontiers in Bioscience - Scholar</i> , 2021, 13, 202.	0.8	4
29	Opportunistic screening for hypertension: what does it say about the true epidemiology?. <i>Journal of Human Hypertension</i> , 2022, 36, 364-369.	1.0	3
30	Serum vitamin D in obese and overweight subjects according to estimated glomerular filtration rate. <i>Hormones</i> , 2018, 17, 237-246.	0.9	2
31	Tadalafil in patients on antihypertensive medications: Does safety remain an issue?. <i>Journal of Clinical Hypertension</i> , 2022, 24, 179-181.	1.0	2
32	Hypertension is the crucial link between obstructive sleep apnea and arterial stiffness. <i>Journal of Clinical Hypertension</i> , 2022, 24, 398-400.	1.0	2
33	Serum Uric Acid Levels and Cardiometabolic Profile in Middle-Aged, Treatment-Na ⁺ ve Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, , 1.	1.0	2
34	COVID-19 and Kidney Disease: A Clinical Perspective. <i>Current Vascular Pharmacology</i> , 2022, 20, 321-325.	0.8	2
35	Joint ESH Excellence Centers [™] National Meeting on Renal Sympathetic Denervation: a Greek Experts [™] Survey. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 355-358.	0.4	1
36	Narrative review of recent studies on the role of vitamin D in the prevention of cardiac and renal risk and additional considerations for COVID-19 vulnerability. <i>Current Vascular Pharmacology</i> , 2021, 19, .	0.8	1

#	ARTICLE	IF	CITATIONS
37	Should we need more sensitive early diagnostic markers in children with congenital solitary functioning kidneys?. Journal of Clinical Hypertension, 2021, 23, 253-256.	1.0	0
38	Chronic Pain and Its Association with Depressive Symptoms and Renal Function in Hypertensive Patients. International Journal of Environmental Research and Public Health, 2022, 19, 1899.	1.2	0
39	Prognostic significance of risk factors and biomarkers in patients hospitalized for cardiorenal syndromes: A pilot study. Current Medicinal Chemistry, 2022, 29, .	1.2	0